Ony Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 1985 and based in Amherst, New York, ONY Biotech is a commercial-stage biotech specializing in neonatal respiratory care. Its core business is built on the FDA-approved surfactant Infasurf®, which has been a standard of care since 1998. The company is actively expanding its portfolio through clinical development of non-invasive surfactant delivery (InfasurfAero™) and partnerships for medical devices like the AerVia® Neonatal Airway, aiming to solidify its position as a leader in neonatology therapeutics and devices.

NeonatologyRespiratory Distress Syndrome

Technology Platform

Proprietary expertise in natural lung surfactant (calfactant) extraction, formulation, and manufacturing, with a next-generation focus on non-invasive aerosolized delivery platforms for neonatal respiratory therapy.

Opportunities

The successful development and approval of InfasurfAero™ represents a paradigm-shifting opportunity to expand the use of surfactant therapy to a broader population of preterm infants through non-invasive delivery, potentially capturing significant new market share.

Additionally, leveraging existing international partnerships and expanding the portfolio of neonatal devices and therapies can transform ONY into a comprehensive solutions provider for NICUs globally.

Risk Factors

The company faces significant dependency risk on its flagship product Infasurf®, with revenue vulnerable to competition and pricing pressures.

The clinical and regulatory success of the key pipeline asset, InfasurfAero™, is uncertain, and failure would impair growth prospects.

Operating in a specialized but competitive niche, ONY also risks being outmaneuvered by larger firms with greater R&D and commercial resources.

Competitive Landscape

ONY Biotech competes in the established lung surfactant market against other animal-derived products (e.g., Survanta®/beractant) and synthetic surfactants. Its growth strategy via non-invasive delivery (InfasurfAero™) places it in a emerging, less crowded segment where it could gain a first-mover advantage. In devices, it competes with other neonatal airway device manufacturers, leveraging its deep relationships within NICUs.

More companies in Small Molecule Drugs →More companies in United States →